These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34504785)

  • 1. A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
    Li Y; Cheng L; Xu C; Chen J; Hu J; Liu N; Lan S; Xie J; Sun T; Wang L; Zhang Y; Sun Y; Chen S; Hu L
    Front Oncol; 2021; 11():702239. PubMed ID: 34504785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation.
    Zhu J; Wang Q; Ren H; Dong Y; Yin Y; Wang Q; Liang Z; Liu W; Wang Q; Wang B; Li Y
    Front Immunol; 2023; 14():1274492. PubMed ID: 37928518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
    Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Decitabine Monotherapy Reverses Mixed Chimerism in Adult Patients After Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimen: A Pilot Phase II Study.
    Wang L; Wang LN; Zhou JF; Gao WH; Jiang CH; Tang W; Zhao WL; Hu J; Jiang JL
    Front Med (Lausanne); 2021; 8():627946. PubMed ID: 33708780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.
    Tang X; Valdez BC; Ma Y; Zhang Q; Qu C; Dai H; Yin J; Li Z; Xu T; Xu Y; Chen J; Zhu X; Chen Z; Wu D; Andersson BS
    Bone Marrow Transplant; 2021 Jul; 56(7):1674-1682. PubMed ID: 33637882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui JK; Xiao Y; You Y; Shi W; Li Q; Luo Y; Jiang L; Zhong ZD
    J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):693-698. PubMed ID: 29058281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.
    Gao J; Hu Y; Gao L; Xiao P; Lu J; Hu S
    BMC Pediatr; 2022 May; 22(1):312. PubMed ID: 35624441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Wang J; Zhao J; Fei X; Yin Y; Cheng H; Zhang W; Gu J; Yang F; Yang Y; Xue S; Tian Z; He J; Zhang S; Wang X
    Medicine (Baltimore); 2018 Apr; 97(17):e0228. PubMed ID: 29702970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
    Sommer S; Cruijsen M; Claus R; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Blijlevens NMA; May A; Duyster J; Huls G; van der Velden WJFM; Finke J; Lübbert M
    Leuk Res; 2018 Sep; 72():20-26. PubMed ID: 30064039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of disease status on outcomes of allogeneic hematopoietic stem cell transplantation in patients with refractory and relapsed acute myeloid leukemia].
    Zhou QL; Tang XW; Sun AN; Qiu HY; Jin ZM; Miao M; Fu ZZ; Zhao BR; Shi XL; Chen GH; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):954-8. PubMed ID: 22931663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease.
    Wang QY; Li Y; Liang ZY; Yin Y; Liu W; Wang Q; Dong YJ; Sun YH; Xu WL; Ren HY
    Cancer Manag Res; 2019; 11():10195-10203. PubMed ID: 31824191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
    Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
    Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
    Yao W; Chu X; Fang X; Zhu X; Tang B; Wan X; Geng L; Tong J; Song K; Zhang X; Qiang P; Sun G; Liu H; Sun Z
    J Clin Pharm Ther; 2020 Dec; 45(6):1372-1381. PubMed ID: 33010180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.